23.25

2.92% -0.70

Neurogene Inc (NGNE)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Neurogene Inc stock is traded at $23.25, with a volume of 571.50K. It is down -2.92% in the last 24 hours and down -32.94% over the past month. Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Previous Close:

$23.95

Open:

$24

24h Volume:

571.50K

Relative Volume:

1.45

Market Cap:

$465.26M

Revenue:

$925.00K

Net Income/Loss:

$-98.64M

P/E Ratio:

-4.6323

EPS:

-5.0191

Net Cash Flow:

$-83.37M

1W Performance:

-11.93%

1M Performance:

-32.94%

6M Performance:

-9.29%

1Y Performance:

-31.60%

1-Day Range:

$23.00

$24.27

1-Week Range:

$21.05

$27.15

52-Week Range:

$15.93

$43.66

Neurogene Inc Stock (NGNE) Company Profile

Name

Neurogene Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

(877) 237-5020

Address

535 W 24TH STREET, NEW YORK

Employee

131

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

NGNE's Discussions on Twitter

Compare NGNE vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NGNE Neurogene Inc	23.25	465.26M	925.00K	-98.64M	-83.37M	-5.0191
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-08-26	Initiated	JP Morgan	Overweight
Jun-03-26	Initiated	Rodman & Renshaw	Buy
Jun-17-25	Initiated	Craig Hallum	Buy
May-16-25	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-29-24	Initiated	Leerink Partners	Outperform
Mar-21-24	Initiated	William Blair	Outperform
Jan-08-24	Initiated	H.C. Wainwright	Buy
Jan-05-24	Initiated	Stifel	Buy
Jan-04-24	Initiated	TD Cowen	Outperform

View All

Neurogene Inc Stock (NGNE) Latest News

Oct 13, 2026

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research

Oct 13, 2026

Oct 07, 2026

Prudential reports a passive Neurogene (NGNE) stake spanning more than 2 million shares. - Stock Titan

Oct 07, 2026

Oct 06, 2026

A passive investor reports 2.23 million shares of Neurogene (NGNE). - Stock Titan

Oct 06, 2026

Oct 05, 2026

Five new hires’ options vest over four years, if they stay - Stock Titan

Oct 05, 2026

Oct 02, 2026

Form 4 Neurogene Inc For: 2 October By Investing.com - Investing.com South Africa

Oct 02, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Sep 07, 2026

Sep 04, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Sep 04, 2026

Aug 30, 2026

Certain Stock Options of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026. - marketscreener.com

Aug 30, 2026

Certain Pre-Funded Warrants of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026. - marketscreener.com

Aug 30, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Expands Neurogene Inc (NGNE) Stak - GuruFocus

Aug 20, 2026

Neurogene (NGNE) Watch: Posts a 4.45% Loss to $37.67 in the Current Update; Trading Range: Support at $35.79 and Resistance at $39.55 Frame the Range on the DayMarket Leader Picks - vinanet.vn

Aug 20, 2026

Neurogene (NGNE) Latest Quarter: Profit Per Share Falls Below Its Benchmark in Latest Trading; Market Response: Shares Finish 10.54% Higher in the Current UpdateLong-Term Guidance - dars.gov.et

Aug 20, 2026

Neurogene (NGNE) Latest Quarter: Profit Per Share Falls Below Its Benchmark in Latest Trading; Market Response: Shares Finish 10.54% Higher in the Current UpdateFull Year Guidance - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Neurogene (NGNE) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Response: Shares Rise 10.54% for the Current SessionGuidance Upgrade Report - vinanet.vn

Aug 19, 2026

Neurogene gearing up to apply for approval of Rett gene therapy - Rett Syndrome News

Aug 19, 2026

Neurogene (NGNE) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Response: Shares Rise 10.54% for the Current SessionBalance Sheet Strength - dars.gov.et

Aug 19, 2026

Aug 16, 2026

NGNE Q1 2026 Earnings: Narrow EPS Miss Masks Positive Investor SentimentEarnings Forecast Report - vinanet.vn

Aug 16, 2026

Neurogene (NGNE) Gains 1.43% to $36.14: Key Resistance at $37.95 in FocusMoney Flow Index - vinanet.vn

Aug 16, 2026